Metformin, Careprost, Sildenafil, Tadalafil

All product prices are in US dollars.
US Brand Name Pneumo 23
Generic Name Polysaccharide Pneumococcal Vaccine
Other Brand Name Pneumo 23
Packing 1
Manufacturer Sanofi Pasteur
Form Injection Syringe
Strength 25 mcg x 0.5ml

  • 25mcg x 0.5ml Vaccine Injection Syringe $57.72
Out of Stock. Please contact us for Availability.
More Views

Customers also bought

  • Generic Avalide, Irbesartan/ Hydrochlorothiazide

    Generic Name:Irbesartan/ Hydrochlorothiazide
    Form:Tablet
    Out of Stock
  • Festal-N

    Generic Name:Pancreatin
    Form:Tablet
< >

1 1

Similar Product

  • Mucopolysaccharide Polysulphate Cream

    Generic Name:Mucopolysaccharide Polysulphate
    Form:Cream
  • Hiberix Injection

    Generic Name:Tetanus Toxoid
    Form:Vial
  • Mencevax ACWY Mono Dose  Injection

    Generic Name:Meningococcal Vaccine (Group A, C, Y & W-135)
    Form:Vial
    Out of Stock
  • T-heal, Muco-polysaccharides / Collagen(Type 1) / VitaminC

    Generic Name: Muco-polysaccharides / Collagen(Type 1) / VitaminC
    Form: Capsules
  • Hirudal Cream, Mucopolysaccharide Polysulfate

    Generic Name:Mucopolysaccharide Polysulfate
    Form:Cream
< >

1 1 1 1 1

Details

Introduction

The drug is a pneumococcal polysaccharide vaccine derived from capsular polysaccharide that increases the body's defence against infection with pneumococcal bacteria by introducing minute quantities of antibodies in to the blood stream that fights well against the invading organism. The product is designed to prevent infection that is caused by most common type of pneumonia causing bacteria. It is well used for both noscomial as well as severe systemic pneumonia. Everyone above 2 years of age or older with risks of pneumococcal pneumonia should be given the vaccine. The product has served well in reducing the deaths due to pneumococcal diseases in a cost effective manner.


Use

The product is indicated in persons 2 years of age or older for the prevention of invasive infection, such as bacteraemia, pneumonia or meningitis, caused by the serotypes of pneumococci contained in the vaccine. The product is also indicated in persons with increased risk of invasive pneumococcal infection.


Side effects

Use of the product may result in injection-site pain/soreness/tenderness, injection-site swelling/induration, headache, injection-site erythema, asthenia/fatigue, and myalgia. The product may cause anaphylactic reaction in sensitive individual. The vaccine might show signs of vomiting and nausea as well as abdominal discomfort.


Contraindication

The vaccine should not be used in Individuals with a history of anaphylactic reaction. It should be given to pregnant women only if clearly needed. The product should not be given to children under 2 years of age.


storage

The unopened and opened vials should be stored at 2-8 degree Celsius. The product should be kept away from reach of children. All the vaccines must be discarded after the expiration date.


Composition

The vaccine PNEUMO 23-Pneumococcal Polysaccharide Vaccine is a clear, colourless liquid prepared from purified pneumococcal capsular antigens. Each dose which is 0.5ml contains: Purified Streptococcus pneumonia polysaccharides, 25 μg of each of the following serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F ,phenol less than 1.25 mg ,sodium chloride 4.150 mg ,disodium phosphate 0.065 mg ,monosodium phosphate 0.023 mg ,water for injection q.s. 0.5 mL.


Important Precautions

Caution and appropriate care should be exercised in administering PNEUMO 23 to individuals with severely compromised cardiovascular and or pulmonary function in whom a systemic reaction may cause fatal risk. Cardiac monitoring should be cautiously done in such individuals. Persons requiring penicillin prophylaxis should not be discontinued. Persons with immunosuppressive therapy may show diminished response to the vaccine.


Dosage and administration

The product is indicated in persons 2 years of age or older for the prevention of invasive infection, such as bacteraemia, pneumonia or meningitis, caused by the serotypes of pneumococci contained in the vaccine. The product is also indicated in persons with increased risk of invasive pneumococcal infection.